01951     2200181   4500001002100000005001500021008004100036020001400077035001900091041000700110100001600117245010200133250001900235260002500254300003600279500127900315650017501594INLIS00000000000008120210323091255210323|||||||||   |   |||   |||| ||   |   a0852-9612  0010-0321000081  aid0 aPudjiatmoko00aRespon pembentukan antibodi pada tikus putih terhadap vaksin ompA-Recombinant Feline Chlamydiosis  avol. 8, p.8-14  aBogorbBBPMSOHc2001  a4 tables. 11 ref.; Summary (En)  aThe omp A-recombinant protein produced by E.coli BL21 (DE3)plysS containing pRSETA/ompA gene of feline Chlamydia psittaci B166 strain was purified using method of Xpress system protein purification (invitrogen BV, The Netherlands). To eliminate guanidine hydrochloride, the suspension of ompA-recombinant protein was dialyzed in 20 mM Tris pH 7.8, glycerol 10% and phenylmethylsulfonyl fluoride containing 0,1 M Mgcl2, CaCl2, NaCl or KCl. To prepare the vaccines, the purified proteins were emulsified with oil adjuvant. One ml of each vaccine was injected intramuscularly to 4 spesific pathogen free rats 8-week-old. The second vaccination was performed at 3 weeks post first vaccination. IgG antibody titer against feline Chlamydia psittaci was measured using microimmunofluorescene test at a week post second vaccination. Vaccination using ompA-recombinant could initiate IgG antibody in 21 of 24 vaccinated rats. IgG antibody titer or rats vaccinated with materials dialyzed in dialysis buffer containing KCl has highest titer ranged from 1:16 to 1:64, and its geometric mean titer is 1:38. The results of the present study indicate that the ompA-recombinant protein of chlamydia used for main component of vaccine my initiate antibody against feline C. psittaci in rats 0aCats -- Escherichia coli -- Rats -- ANTIBODIES -- IMMUNO FLUORESCENCE -- Chlamydia Psittaci -- Bacteriosis -- Synthetic Vaccine -- Protein -- Specific Pathogen Free State